Phase II trial of temsirolimus in patients with metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 136, Issue 2, 2012, Pages 355-363

  Fleming, Gini F ^a   Ma, Cynthia X ^a,b   Huo, Dezheng ^a   Sattar, Husain ^a   Tretiakova, Maria ^a   Lin, L ^a,b   Hahn, Olwen M ^a   Olopade, F O ^a   Nanda, R ^a   Hoffman, Philip C ^a   Naughton, M J ^a,b   Pluard, Timothy ^a,b   Conzen, Suzanne D ^a   Ellis, Matthew J ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Breast cancer; PIK3CA; PTEN; Rapamycin; Temsirolimus; Treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FORMALDEHYDE; MAMMALIAN TARGET OF RAPAMYCIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; TEMSIROLIMUS;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST METASTASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; ENZYME ACTIVE SITE; FATIGUE; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MUCOSA INFLAMMATION; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; TISSUE SECTION; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84868195516     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1910-7     Document Type: Article

References (35)

1. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P et al (2001) mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8(3):249-258
2. Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102(3):802-807
3. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK et al (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15(16):5049-5059
4. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554-2559
5. Hernandez-Aya LF, Gonzalez-Angulo AM (2011) Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16(4):404-414
6. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D et al (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69(1):143-150
7. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23(23):5314-5322
8. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J et al (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10(3):1013-1023
9. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S et al (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27(27):4536-4541
10. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M et al (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13(20):6064-6069
11. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630-2637
12. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS et al (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Res 10(3):558-565
13. Oza AM, Elit L, Tsao M-S, Kamel-Reid S, Biagi J, Provencher DM et al (2011) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J Clin Oncol 29(24):3278-3285
14. Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W et al (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17(4):667-677
15. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA et al (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10(6):1093-1101
16. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J et al (2010) Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119(2):379-390
17. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98(18):10314-10319
18. Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W et al (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62(17):5027-5034
19. Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH et al (2008) Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27(29):4086-4095
20. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M et al (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084-6091
21. Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M et al (2010) Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: In silico and biological evaluations. Cancer Res 70(12):4982-4994
22. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T et al (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120(8):2858-2866
23. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H et al (2009) Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 106(52):22299-22304
24. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68(19):8022-8030
25. Weigelt B, Warne PH, Downward J (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30(29):3222-3233
26. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA et al (2010) Predictive biomarkers of sensitivity to the phosphatidylinositol 30 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16(14):3670-3683
27. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M et al (2008) Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 10(6):R101
28. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65(16):7052-7058
29. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117-127
30. Clark AS, West K, Streicher S, Dennis PA (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1(9):707-717
31. Bachelot T, Bourgier C, Cropet C, Guastalla JP, Ferrero JM, Leger-Falandry C et al (2010) TAMRAD: A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). San Antonio Breast Conference
32. Bhattacharyya GS, Biswas J, Singh JK, Singh M, Govindbabu K, Ranade AA et al (2011) Breast cancer-early and advanced disease: Breast cancer-advanced disease. European Multidisciplinary Cancer Congress
33. Dalenc F, Campone M, Hupperets P, O'Regan R, Manlius C, Vittori L et al (2010) Everolimus in combinatoin with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multcenter phase II clinical trial. J Clin Oncol 28(15S):117s
34. Morrow PH, Wulf GM, Booser DJ, Moore JA, Flores PR, Krop IE et al (2010) Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer. J Clin Oncol 28S(15):117s
35. Chow LWC, Sun Y, Jassem J, Baselga J, Hayes DF, Wolff AC et al (2006) Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 100(1):s286